These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 25152576)

  • 1. Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.
    Knab LM; Grippo PJ; Bentrem DJ
    World J Gastroenterol; 2014 Aug; 20(31):10729-39. PubMed ID: 25152576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The different inhibitory effects of Huang-Lian-Jie-Du-Tang on cyclooxygenase 2 and 5-lipoxygenase.
    Li L; Zeng H; Shan L; Yuan X; Li Y; Liu R; Zhang W
    J Ethnopharmacol; 2012 Sep; 143(2):732-9. PubMed ID: 22884869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells.
    Ganesh R; Marks DJ; Sales K; Winslet MC; Seifalian AM
    World J Surg Oncol; 2012 Sep; 10():200. PubMed ID: 23013454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celastrol modulates inflammation through inhibition of the catalytic activity of mediators of arachidonic acid pathway: Secretory phospholipase A
    Joshi V; Venkatesha SH; Ramakrishnan C; Nanjaraj Urs AN; Hiremath V; Moudgil KD; Velmurugan D; Vishwanath BS
    Pharmacol Res; 2016 Nov; 113(Pt A):265-275. PubMed ID: 27597642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis.
    Polito F; Bitto A; Irrera N; Squadrito F; Fazzari C; Minutoli L; Altavilla D
    Br J Pharmacol; 2010 Nov; 161(5):1002-11. PubMed ID: 20977452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
    Rao CV; Janakiram NB; Madka V; Devarkonda V; Brewer M; Biddick L; Lightfoot S; Steele VE; Mohammed A
    Oncotarget; 2015 Oct; 6(32):33290-305. PubMed ID: 26429877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2.
    Zhang B; Wang CL; Zhao WH; Lv M; Wang CY; Zhong WX; Zhou WY; Yu WS; Zhang Y; Li S
    World J Gastroenterol; 2008 Apr; 14(16):2494-500. PubMed ID: 18442195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different forms of vitamin E and metabolite 13'-carboxychromanols inhibit cyclooxygenase-1 and its catalyzed thromboxane in platelets, and tocotrienols and 13'-carboxychromanols are competitive inhibitors of 5-lipoxygenase.
    Park NY; Im S; Jiang Q
    J Nutr Biochem; 2022 Feb; 100():108884. PubMed ID: 34710615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells.
    Ding XZ; Iversen P; Cluck MW; Knezetic JA; Adrian TE
    Biochem Biophys Res Commun; 1999 Jul; 261(1):218-23. PubMed ID: 10405349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway.
    Tong WG; Ding XZ; Witt RC; Adrian TE
    Mol Cancer Ther; 2002 Sep; 1(11):929-35. PubMed ID: 12481414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of COX-2/mPGES-1 and 5-LOX in macrophages by leonurine ameliorates monosodium urate crystal-induced inflammation.
    Liu Y; Duan C; Chen H; Wang C; Liu X; Qiu M; Tang H; Zhang F; Zhou X; Yang J
    Toxicol Appl Pharmacol; 2018 Jul; 351():1-11. PubMed ID: 29763636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of spirostanol glycosides and furostanol glycosides from anemarrhenae rhizoma as dual targeted inhibitors of 5-lipoxygenase and Cyclooxygenase-2 by employing a combination of affinity ultrafiltration and HPLC/MS.
    Xie L; Lee DY; Shang Y; Cao X; Wang S; Liao J; Zhang T; Dai R
    Phytomedicine; 2020 Oct; 77():153284. PubMed ID: 32707371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput screening assays for cyclooxygenase-2 and 5-lipoxygenase, the targets for inflammatory disorders.
    Kumar KA; Reddy TC; Reddy GV; Reddy DB; Mahipal SV; Sinha S; Gaikwad AN; Reddanna P
    Indian J Biochem Biophys; 2011 Aug; 48(4):256-61. PubMed ID: 22053694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eicosanoid pathway in colorectal cancer: Recent updates.
    Tuncer S; Banerjee S
    World J Gastroenterol; 2015 Nov; 21(41):11748-66. PubMed ID: 26557000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetically-tailored and nature-derived dual COX-2/5-LOX inhibitors: Structural aspects and SAR.
    Meshram MA; Bhise UO; Makhal PN; Kaki VR
    Eur J Med Chem; 2021 Dec; 225():113804. PubMed ID: 34479036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of 5-Lipoxygenase-Derived Leukotrienes and Hemiketals as a Novel Anti-Inflammatory Mechanism of Urolithins.
    Giménez-Bastida JA; González-Sarrías A; Espín JC; Schneider C
    Mol Nutr Food Res; 2020 Jun; 64(11):e2000129. PubMed ID: 32306507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities.
    Ghatak S; Vyas A; Misra S; O'Brien P; Zambre A; Fresco VM; Markwald RR; Swamy KV; Afrasiabi Z; Choudhury A; Khetmalas M; Padhye S
    Bioorg Med Chem Lett; 2014 Jan; 24(1):317-24. PubMed ID: 24295787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
    Cai H; Huang X; Xu S; Shen H; Zhang P; Huang Y; Jiang J; Sun Y; Jiang B; Wu X; Yao H; Xu J
    Eur J Med Chem; 2016 Jan; 108():89-103. PubMed ID: 26638042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.
    Ding X; Zhu C; Qiang H; Zhou X; Zhou G
    Biomed Pharmacother; 2011 Oct; 65(7):486-90. PubMed ID: 21993002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis.
    Bäck M
    Curr Pharm Des; 2009; 15(27):3116-32. PubMed ID: 19754386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.